Release date: 2026-10-21 14:03:44 Recommended: 3
Indicated for the treatment of adult and pediatric patients 12 years of age and older with Grade 2 astrocytoma or oligodendroglioma harboring an IDH1 or IDH2 mutation as detected by an FDA-approved